Abstract
Cellular transformation induces phenotypically diverse populations of tumour-infiltrating T cells1,2,3,4,5, and immune checkpoint blockade therapies preferentially target T cells that recognize cancer cell neoantigens6,7. Yet, how other classes of tumour-infiltrating T cells contribute to cancer immunosurveillance remains elusive. Here, in a survey of T cells in mouse and human malignancies, we identified a population of αβ T cell receptor (TCR)-positive FCER1G-expressing innate-like T cells with high cytotoxic potential8 (ILTCKs). These cells were broadly reactive to unmutated self-antigens, arose from distinct thymic progenitors following early encounter with cognate antigens, and were continuously replenished by thymic progenitors during tumour progression. Notably, expansion and effector differentiation of intratumoural ILTCKs depended on interleukin-15 (IL-15) expression in cancer cells, and inducible activation of IL-15 signalling in adoptively transferred ILTCK progenitors suppressed tumour growth. Thus, the antigen receptor self-reactivity, unique ontogeny, and distinct cancer cell-sensing mechanism distinguish ILTCKs from conventional cytotoxic T cells, and define a new class of tumour-elicited immune response.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
All processed single-cell RNA-seq and bulk RNA-seq data that support the findings of this study have been deposited with the Gene Expression Omnibus under accession code GSE195937. Previously published single-cell RNA-seq data reanalysed here are available under accession code GSE108989. Source data are provided with this paper.
References
Zheng, C. et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 169, 1342–1356.e1316 (2017).
Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293–1308.e1236 (2018).
Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575–579 (2018).
Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268–272 (2018).
Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).
Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).
Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. New Engl. J. Med. 377, 2500–2501 (2017).
Dadi, S. et al. Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell 164, 365–377 (2016).
DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F. & Jacks, T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482, 405–409 (2012).
Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400–404 (2012).
Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017).
McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 37, 457–495 (2019).
Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).
Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275–287 (2016).
Baumeister, S. H., Freeman, G. J., Dranoff, G. & Sharpe, A. H. Coinhibitory pathways in immunotherapy for cancer. Annu. Rev. Immunol. 34, 539–573 (2016).
Schneider, W. M., Chevillotte, M. D. & Rice, C. M. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 32, 513–545 (2014).
Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019).
Savage, P. A. et al. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 319, 215–220 (2008).
Ise, W. et al. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat. Immunol. 11, 129–135 (2010).
Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8α+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097–1100 (2008).
Starr, T. K., Jameson, S. C. & Hogquist, K. A. Positive and negative selection of T cells. Annu. Rev. Immunol. 21, 139–176 (2003).
Eberl, G. & Littman, D. R. Thymic origin of intestinal αβ T cells revealed by fate mapping of RORγ+ cells. Science 305, 248–251 (2004).
Georgiev, H., Peng, C., Huggins, M. A., Jameson, S. C. & Hogquist, K. A. Classical MHC expression by DP thymocytes impairs the selection of non-classical MHC restricted innate-like T cells. Nat. Commun. 12, 2308 (2021).
Stritesky, G. L., Jameson, S. C. & Hogquist, K. A. Selection of self-reactive T cells in the thymus. Annu. Rev. Immunol. 30, 95–114 (2012).
Ruscher, R., Kummer, R. L., Lee, Y. J., Jameson, S. C. & Hogquist, K. A. CD8αα intraepithelial lymphocytes arise from two main thymic precursors. Nat. Immunol. 18, 771–779 (2017).
Gazit, R. et al. Fgd5 identifies hematopoietic stem cells in the murine bone marrow. J. Exp. Med. 211, 1315–1331 (2014).
Ruscher, R. et al. Intestinal CD8αα IELs derived from two distinct thymic precursors have staggered ontogeny. J. Exp. Med. 217, e20192336 (2020).
Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211–218 (2019).
Alfei, F. et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571, 265–269 (2019).
Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270–274 (2019).
Chinen, T. et al. An essential role for the IL-2 receptor in Treg cell function. Nat. Immunol. 17, 1322–1333 (2016).
Correia, M. P. et al. Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential. Proc. Natl Acad. Sci. USA 115, E5980–E5989 (2018).
Perarnau, B. et al. Single H2Kb, H2Db and double H2KbDb knockout mice: peripheral CD8+ T cell repertoire and anti-lymphocytic choriomeningitis virus cytolytic responses. Eur. J. Immunol. 29, 1243–1252 (1999).
Sosinowski, T. et al. CD8α+ dendritic cell trans presentation of IL-15 to naive CD8+ T cells produces antigen-inexperienced T cells in the periphery with memory phenotype and function. J. Immunol. 190, 1936–1947 (2013).
Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).
Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902.e1821 (2019).
Angerer, P. et al. destiny: diffusion maps for large-scale single-cell data in R. Bioinformatics 32, 1241–1243 (2016).
Haghverdi, L., Buettner, F. & Theis, F. J. Diffusion maps for high-dimensional single-cell analysis of differentiation data. Bioinformatics 31, 2989–2998 (2015).
Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381–386 (2014).
Qiu, X. et al. Single-cell mRNA quantification and differential analysis with Census. Nat. Methods 14, 309–315 (2017).
Qiu, X. et al. Reversed graph embedding resolves complex single-cell trajectories. Nat. Methods 14, 979–982 (2017).
Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12, 357–360 (2015).
Mudge, J. M. & Harrow, J. Creating reference gene annotation for the mouse C57BL6/J genome assembly. Mamm. Genome 26, 366–378 (2015).
Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 41, e108 (2013).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284–287 (2012).
Yang, Y. et al. Distinct mechanisms define murine B cell lineage immunoglobulin heavy chain (IgH) repertoires. eLife 4, e09083 (2015).
Wang, C. et al. High-throughput, high-fidelity HLA genotyping with deep sequencing. Proc. Natl Acad. Sci. USA 109, 8676–8681 (2012).
Lefranc, M. P. et al. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. 27, 209–212 (1999).
Franklin, R. A. et al. The cellular and molecular origin of tumor-associated macrophages. Science 344, 921–925 (2014).
Gasteiger, G., Fan, X., Dikiy, S., Lee, S. Y. & Rudensky, A. Y. Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs. Science 350, 981–985 (2015).
Morita, S., Kojima, T. & Kitamura, T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 7, 1063–1066 (2000).
Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).
Mayans, S. et al. αβT cell receptors expressed by CD4−CD8 αβ intraepithelial T cells drive their fate into a unique lineage with unusual MHC reactivities. Immunity 41, 207–218 (2014).
McDonald, B. D., Bunker, J. J., Ishizuka, I. E., Jabri, B. & Bendelac, A. Elevated T cell receptor signaling identifies a thymic precursor to the TCR αβ+CD4−CD8β− intraepithelial lymphocyte lineage. Immunity 41, 219–229 (2014).
Constantinides, M. G., McDonald, B. D., Verhoef, P. A. & Bendelac, A. A committed precursor to innate lymphoid cells. Nature 508, 397–401 (2014).
Acknowledgements
We thank members of the M.O.L. laboratory for discussions. This work was supported by the National Institute of Health (R01 CA243904-01A1 to M.O.L., F30 AI29273-03 to B.G.N., and F31 CA210332 to M.H.D.), a Howard Hughes Medical Institute Faculty Scholar Award (M.O.L.), a CLIP grant from Cancer Research Institute (M.O.L.), the Ludwig Center for Cancer Immunotherapy and the Functional Genomic Initiative grants (M.O.L.), and the Memorial Sloan Kettering Cancer Center (MSKCC) Support Grant/Core Grant (P30 CA08748). C.C., X.Z. and S.L. are Cancer Research Institute Irvington Fellows supported by the Cancer Research Institute. E.G.S. is a recipient of a Fellowship from the Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center of MSKCC.
Author information
Authors and Affiliations
Contributions
C.C., X.Z. and M.O.L. were involved in all aspects of this study, including planning and performing experiments, analysis and interpretation of data, and writing the manuscript. C.K. and C.S.L. assisted with scRNA-seq and RNA-sequencing analyses. B.G.N., S.D., K.J.C., E.R.K., A.S., J.Z., E.G.S., M.L., S.L., M.H.D., C.E. and D.S.K. performed experiments and assisted with mouse colony management. M.S. and J.H. assisted with single-cell TCR-sequencing experiments. C.-T.C., I.H.W., E.P.P., M.R.W., J.G.-A. and J.J.S. assisted with the acquisition of human samples.
Corresponding author
Ethics declarations
Competing interests
MSKCC has filed a patent application regarding use of ILTCK in cancer immunotherapy. M.O.L. is a member of the scientific advisory board of and holds equity or stock options in Amberstone Biosciences Inc. and META Pharmaceuticals Inc.
Peer review
Peer review information
Nature thanks the anonymous reviewers for their contribution to the peer review of this work. Peer review reports are available.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data figures and tables
Extended Data Fig. 1 scRNA-seq analysis of tumor-infiltrating CD8+ T cells.
Heat map of the expression levels of selected genes in different clusters.
Extended Data Fig. 2 Distinct developmental trajectories underlie the evolutionarily conserved αβILTCK responses.
a, b, Monocle pseudotime analysis showing hypothetical developmental trajectories of indicated tumor-infiltrating CD8+ T cell subsets using recently activated cells as a starting population. c, Uniform manifold approximation and projection (UMAP) of CD45+TCRβ+CD8α+ lymphocytes isolated from breast tumor tissues of PyMT mice. d, Violin plots showing the enrichment of αβILTCK gene signature in the indicated cell clusters from PyMT mice. e, Enrichment of αβILTCK signature genes in cluster C3 from PyMT mice. f, UMAP of CD8+ T cells isolated from prostate tumor tissues of TRAMP mice. g, Enrichment of αβILTCK gene signature in the indicated cell clusters from TRAMP mice. h, Enrichment of αβILTCK signature genes in cluster C3 from TRAMP mice. i, UMAP of CD8+TCRαβ+ T cells present in a previously published human colorectal carcinoma dataset12. j, Violin plots showing enrichment of αβILTCK gene signature in various cell clusters from the human colorectal carcinoma tissues. k, Enrichment of αβILTCK signature genes in cluster C3 from the human colorectal carcinoma dataset.
Extended Data Fig. 3 Recognition of cancer cell antigens by NK1.1+ αβILTCK-TCRs.
a, A representative flow plot showing the gating strategy used to isolate NK1.1+ αβILTCKs and PD-1+ T cells (TCs) from PyMT mice. NK1.1+ αβILTCKs are identified as CD45+TCRβ+CD8α+PD-1–NK1.1+ whereas PD-1+ TCs are defined as CD45+TCRβ+CD8α+PD-1+NK1.1–. b, A histogram showing the distribution of CDR3 lengths of TCRα and TCRβ pairs isolated from αβILTCks and PD-1+ TCs. Data are pooled from two independent experiments. c, Flow cytometric analysis showing the frequency of GFP+ cells among CD8+ and CD8– reporter cell line expressing indicated TCRs 24 h after co-culturing with primary PyMT cancer cells or splenocytes pulsed with the SIINFEKL peptide (OVA257-264). Data are representative of three independent experiments. d, Frequency of GFP+ cells among CD8– reporter cell line expressing indicated NK1.1+ αβILTCK-derived TCRs 24 h after co-culturing with primary PyMT cancer cells. n = 3 for each TCR. All statistical data are shown as mean ± S.D (biologically independent mice in a–c and independent samples in d).
Extended Data Fig. 4 The majority of αβILTCKs recognize tumor-associated antigens presented in the context of classical MHC-I.
a, A representative flow plot showing the expression of classical MHC-I (H2-Kb and H2-Db) on PyMT cancer cells, defined as CD45–CD31–EpCAM+ from mice of indicated genotypes. Data are representative of two independent experiments. b, Frequency of GFP+ cells among CD8+ reporter cell line expressing indicated TCRs 24 h after co-culturing with primary PyMT cancer cells doubly deficient for H2-Kb and H2-Db. Data are pooled from three independent experiments. c, Flow cytometric analysis showing the frequency of GFP+ cells among CD8+ and CD8– reporter cell line expressing the indicated TCRs 24 h after co-culturing with primary PyMT cancer cells lacking β2m. Data are representative of two independent experiments. d, Frequency of TCRβ+CD8α+ cells among CD45+ tumor-infiltrating cells in mice lacking classical MHC-I (H2-K1–/–H2-D1–/–, n = 3), both classical and non-classical MHC-I (B2m–/–, n = 3) or control wild-type mice (n = 7). The profiles of PD-1 and NK1.1 expression by TCRβ+CD8α+ are shown in the bottom panel. e, Statistical analysis of frequency of PD-1+ T cells and αβILTCKs among tumor-infiltrating CD45+ cells in mice of indicated genotypes. f, Flow cytometric analysis showing H-2Db expression on control, TAP1- or β2m-deficient PyMT cell lines generated by Cas9-mediated genome editing with small guide RNA (sgRNA). g, Expression of GFP in reporter cell lines expressing the indicated TCRs 24 h after co-culture with control or TAP1-deficient PyMT cells lines in the presence of absence of SIINFEKL peptide. h, Frequency of GFP+ cells among TCR-expressing reporter cells after co-culture with PyMT cell lines of indicated genotypes with or without SIINFEKL peptide. Data are pooled from three independent experiments. All statistical data are shown as mean ± S.D (biologically independent mice in a, c–e and independent samples in b, f–h). **P < 0.01; ***P < 0.001 and n.s.: not significant.
Extended Data Fig. 5 Generation of CD8+ T cells with altered specificity via TCR ‘swapping’.
a, b, A schematic diagram showing the experimental design. Cas9-mediated deletion of endogenously rearranged TCR in CD8+ T cells is achieved by the introduction of three distinct TCR-loci-targeting small guide RNAs (sgRNAs) expressed from a single retrovirus. A TCR of interest is introduced into the TCR-deleted CD8+ T cells by another retrovirus. c, A timeline outlining the steps to generate CD8+ T cells with altered antigen receptor specificity. d, Representative flow plots showing the successful deletion of both the TCRα and TCRβ chains after transduction with sgRNA-expressing retrovirus. e, Flow plots showing the re-expression of surface TCR after retrovirus-mediated introduction of a TCR of interest. f, Representative flow plots showing the colonization of tumor tissues in CD45.2+ recipient mice by CD45.1+CD45.2+ donor CD8+ T cells, which have undergone the ‘swap’ procedure to express the indicated TCRs seven days post adoptive transfer. Data are representative of two independent experiments. Biologically independent mice in f and independent samples in d, e.
Extended Data Fig. 6 αβILTCK development is cDC1-independent.
a, Flow cytometric analysis of TCRβ, CD8α, PD-1, and NK1.1 expression in tumor-infiltrating CD45+ cells from Batf3–/–PyMT (n = 10) and control Batf3+/+PyMT mice (n = 13). b, Frequency of tumor-infiltrating PD-1+ T cells and αβILTCKs in mice of indicated genotypes. c, Flow cytometric analysis of TCRβ, CD8α, PD-1, and NK1.1 expression in tumor-infiltrating CD45+ cells from Itgax-cre-Irf8fl/flPyMT (n = 8) and control Itgax-cre-Irf8+/+PyMT mice (n = 9). d, Frequency of tumor-infiltrating PD-1+ T cells and αβILTCKs in mice of indicated genotypes. All statistical data are shown as mean ± S.D (biologically independent mice in a–d). Two-tailed unpaired t-test in b, d. ****P < 0.0001 and n.s.: not significant.
Extended Data Fig. 7 Recognition of thymus-derived self-antigens by αβILTCK-TCRs specifies αβILTCK lineage commitment from DP thymocytes.
a, Frequency of TCRβ+ cells among donor-derived (GFP+) tumor-infiltrating cells in ‘retrogenic’ TCR bone marrow chimeras. n = 3 for each TCR. b, Expression of PD-1 and NK1.1 by donor-derived tumor-infiltrating T cells expressing indicated αβILTCK-derived TCRs in the TCR ‘retrogenic’ bone marrow chimeras. c, Frequency of PD-1+ or NK1.1+ cells among donor-derived tumor-infiltrating cells expressing the indicated TCRs. n = 3 for each TCR. d, Expression of CD4 and CD8α by donor-derived TCRβ+ thymocytes bearing the indicated TCRs in the TCR ‘regtrogenic’ bone marrow chimeras. e, Frequency of CD4+CD8+, CD4–/dullCD8–/dull, CD4+, and CD8+ T cells among donor-derived TCRβ+ thymocytes expressing the indicated TCRs. n = 3 for TCR. f, Expression of tdTomato by splenic CD19+ cells and intratumoral PD-1+ T cells (TCs) as well as αβILTCKs in Rorc-cre-Rosa26LSL-tdTomatoPyMT mice. Data are representative of two independent experiments. g, Frequency of tdTomato+ cells among each indicated lymphocyte compartment. n = 3. h, Expression of YFP by splenic CD19+ cells, intratumoral PD-1+ TCs as well as αβILTCKs, and thymic iNKT cells in PyMT mice reconstituted with YFP– bone marrow from Zbtb16-cre-Rosa26LSL-YFP mice. i, Frequency of YFP+ cells among indicated lymphocyte compartment. n = 4. j, Surface expression of PD-1 and CD122 on donor-derived TCRβ+ thymocytes bearing the indicated monoclonal TCR in the TCR ‘retrogenic’ bone marrow chimeras. Data are representative of three independent experiments. k, Frequency of PD-1+CD122+ T cells among donor-derived TCRβ+ thymocytes with indicated TCR. n = 3 for NK16, NK28, and NK25, n = 4 for NK186, NK22, and NK139 TCR. l, Frequency of GFP+ cells among CD8+ reporter cell line expressing indicated TCRs 24 h after co-culturing with a cortical thymic epithelial cell line. Data are pooled from two independent experiments. m, Frequency of αβILTCK progenitors (αβILTCKPs) among donor-derived thymocytes expressing the NK139 or NK186 TCRs in B2m+/+ or B2m–/– recipient mice reconstituted with Rag1–/–B2m+/+ bone marrow cells. n = 3 for each TCR. n, Frequency of αβILTCKPs among donor-derived thymocytes in B2m+/+ or B2m–/– recipient mice reconstituted with B2m+/+ or B2m–/– bone marrow cells. n = 3 for each bone marrow chimera. All statistical data are shown as mean ± S.D (biologically independent mice in a–k and independent samples in i). Two-tailed unpaired t-test in c, e, m, n. **P < 0.01; ***P < 0.001 and n.s.: not significant.
Extended Data Fig. 8 Continuous replenishment of the intratumoral αβILTCK compartment by circulating progenitors.
a, Flow cytometric analysis of CD8α and CD8β co-receptor expression on donor-derived T cells bearing the indicated monoclonal TCR in the tumor and small intestinal (S.I.) epithelium from TCR ‘retrogenic’ bone marrow chimeras. Data are representative of three independent experiments. b, Frequency of CD8αα+ and CD8αβ+ cells among donor TCRβ+ cells in the small intestine epithelium. c, Frequency of CD8αα+ and CD8αβ+ cells among donor TCRβ+ cells in PyMT tumors. Data are pooled from three independent experiments. d, A gating strategy for isolating the putative αβILTCK-committed thymic progenitors (αβILTCKPs). αβILTCKPs are defined as CD4–/dullCD8–/dullTCRβ+CD1d–CD25–PD-1+CD122+NK1.1–. Data are representative of three independent experiments. e, A schematic diagram showing the experimental setup to assess the differentiation potential of putative αβILTCKPs. f, Tracking the contribution of adult bone marrow hematopoiesis to various lymphocyte lineages. Fgd5-creER-Rosa26LSL-tdTomatoPyMT mice were administered 5 mg of Tamoxifen via oral gavage, and lymphocytes in multiple organs were analyzed 21 weeks later for tdTomato expression. g, Flow plots showing tdTomato expression in bone marrow lineage–c-Kit+Sca1+ (LSK) hematopoietic stem cells from Fgd5-creER-Rosa26LSL-tdTomatoPyMT mice 21 weeks post Tamoxifen administration. n = 4. h, Flow cytometric analysis showing the expression of tdTomato in indicated thymic progenitors as gated in the left panel. i, Frequency of Fgd5-creER-fate-mapped cells among indicated thymic progenitor populations. n = 4. j, Flow cytometric analysis showing the expression of tdTomato in PD-1+ T cells (TCs) and αβILTCK as gated in the left panel. k, Expression of tdTomato and CD8β in TCRβ+CD8α+ cells isolated from the S.I. epithelium. l, Frequency of tdTomato-expressing cells among the indicated lymphocyte populations isolated from the tumor and S.I. epithelium. n = 4. All statistical data are shown as mean ± S.D (biologically independent mice in a–d, g–l). Two-tailed unpaired t-test in b, c, l. *P < 0.05; ***P < 0.001 and n.s.: not significant.
Extended Data Fig. 9 FCER1G and CD122 co-expression identifies αβILTCKs in mouse and human.
a, A scatter plot comparing the gene expression program differentiating αβILTCK-committed thymic progenitors (αβILTCKPs) from CD8 single positive T cells (SPs) (x-axis) to that distinguishing intratumoral αβILTCKs from PD-1+ T cells (TCs) (y-axis). Each dot denotes a gene with the axes representing fold change of the gene expression level. b, Pathway analysis of genes upregulated in thymic αβILTCKPs but subsequently downregulated in intratumoral αβILTCKs. c, A heatmap showing genes downregulated in thymic αβILTCKPs relative to their CD8 SP counterparts. d, A heatmap showing genes upregulated in thymic αβILTCKPs relative to their CD8 SP counterparts. e, Pathway analysis of genes upregulated in intratumoral αβILTCKs compared to their thymic precursors. f, A heat map showing differentially expressed genes among intratumoral PD-1+ TCs, NK1.1+ and NK1.1– αβILTCKs isolated from ‘retrogenic’ bone marrow chimeras generated with NK139 TCR-expressing Rag1–/– bone marrow cells. g, Uniform manifold approximation and projection (UMAP) of CD45+TCRβ+ lymphocytes in breast tumor tissues from PyMT mice showing Fcer1g-expressing cells. h, UMAP of CD45+TCRβ+ lymphocytes in prostate tumor tissues from TRAMP mice showing Fcer1g-expressing cells. i, UMAP of CD45+TCRβ+ lymphocytes present in a previously published human colorectal carcinoma dataset12, showing FCER1G-expressing cells. j, Flow cytometric analysis of FCER1G and CD122 expression in CD4–CD8α–TCRβ+CD1d– and CD8α+TCRβ+CD1d– thymocytes as well as TCRβ+CD4–CD1d–CD8α+NK1.1+ and TCRβ+CD4–CD1d–CD8α+PD-1+ tumor-infiltrating cells from PyMT mice (n = 4). k, Expression levels of FCER1G and CD122 in indicated cell populations. l, Flow cytometric analysis of CD4, CD8α, and CD8β expression in FCER1G+CD122+ and FCER1G–CD122– tumor-infiltrating TCRβ+CD1d– cells from PyMT mice (n = 3). m, Frequency of FCER1G+CD122+ and FCER1G–CD122– tumor-infiltrating TCRβ+CD1d– cells expressing indicator combination of markers. n, Flow cytometric analysis of CD4 and CD8α expression by FCER1G+ and FCER1G– CD45+HLA-DR–TCRβ+ cells in tumor tissues from patients with colon carcinoma. o, Frequency of FCER1G+CD45+HLA-DR–TCRβ+ and FCER1G–CD45+HLA-DR–TCRβ+ tumor-infiltrating cells expressing indicated combination of markers. Data are representative of and pooled from three patient samples. All statistical data are shown as mean ± S.D (biologically independent mice in j–m and human samples in n, o). Two-tailed unpaired t-test in k, m, o. *P < 0.05; **P < 0.01; ***P < 0.001 and n.s.: not significant.
Extended Data Fig. 10 Adoptive transfer of STAT5B-CA-armed αβILTCKs deters tumor growth.
a, Immunofluorescence images showing expression of IL-15 and CDH1 in tumor tissues from patients with colon carcinoma (left panel). Flow cytometric analysis of FCER1G and PD-1 expression in TCRβ+CD4– cells from the same tumor tissue (right panel). Data are representative of two independent experiments. b, Correlation between frequency of PD-1+ cells among CD45+TCRβ+CD4– cells and IL-15 expression level in tumor tissues from patients with colon carcinoma. Each dot denotes an independent patient sample. c, Statistical analysis showing relative mRNA expression of Il15 in sorted CD45–EpCAM+ cancer cells from S100a8-cre-Il15fl/flPyMT (n = 3) and control PyMT mice (n = 3). d, Flow cytometric analysis of PD-1, NK1.1, and granzyme B expression in thymic αβILTCK progenitors (αβILTCKPs) one, three, or five days after culturing in the presence of 100 ng/ml IL-15/IL-15Rα complex. Data are representative of three independent experiments. e, A schematic diagram showing αβILTCK-based adoptive cellular transfer experiment. A constitutively active form of Stat5b (STAT5B-CA) was induced in thymic αβILTCKPs by tamoxifen administration one week after adoptive transfer into lymphocyte-deficient PyMT recipient mice with a total tumor burden of 300–400 mm3. f, Expression of Ly6G and TCRβ by tumor-infiltrating CD45+ cells. g, Statistical analysis of the frequency of donor-derived Ubc-creER-Rosa26+/+ (n = 5) or Ubc-creER-Rosa26LSL-Stat5b-CA/+ (n = 5) TCRβ+ cells among tumor-infiltrating CD45+ cells. h, Flow cytometric analysis of NK1.1 and granzyme B expression by donor-derived TCRβ+ cells in the tumor. i, Frequency of NK1.1+Granzyme B+ cells among transferred TCRβ+ cells. j, Total tumor burden in mice adoptively transferred with no cells or thymic αβILTCKPs of indicated genotypes. Data are pooled from three independent experiments. No transfer (n = 4), Ubc-creER-Rosa26+/+ (n = 8), and Ubc-creER-Rosa26Stat5b-CA/+ (n = 7). k, A schematic diagram showing αβILTCK-based adoptive cellular transfer experiment. STAT5B-CA was induced in thymic CD45.1+CD45.2+ αβILTCK progenitors or CD8 single positive T cells by tamoxifen administration one week after adoptive transfer into congenically distinct CD45.2+ PyMT recipient mice. All statistical data are shown as mean ± S.D (independent human samples in a, b, biologically independent mice in c, f–j and independent cell culture samples in d). Linear regression (b), two-tailed unpaired t-test (c, g, i) and two-way analysis of variance (ANOVA) (j) with post hoc Bonferroni t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 and n.s.: not significant.
Supplementary information
Supplementary Table 1
Unique CDR3 amino acid sequences found in TCRs utilized by tumour-infiltrating αβILTCKs and PD-1+CD8+ T cells (TCs).
Supplementary Table 2
Full-length nucleotide sequences of TCRs used in the TCR reporter assay.
Supplementary Table 3
Differentially expressed genes and associated biological pathways among intratumoural PD-1+CD8+ T cells, αβILTCKs, and their respective thymic precursors.
Supplementary Table 4
Differentially expressed genes between intratumoarl NK1.1+ and NK1.1– αβILTCKs.
Supplementary Table 5
Epidemiological and clinicopathological characteristics of colon cancer patient recruited in the study.
Source data
Rights and permissions
About this article
Cite this article
Chou, C., Zhang, X., Krishna, C. et al. Programme of self-reactive innate-like T cell-mediated cancer immunity. Nature 605, 139–145 (2022). https://doi.org/10.1038/s41586-022-04632-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41586-022-04632-1
This article is cited by
-
Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation
Nature Immunology (2024)
-
Evolution of T cells in the cancer-resistant naked mole-rat
Nature Communications (2024)
-
89Zr-immunoPET-guided selection of a CD33xIL15 fusion protein optimized for antitumor immune cell activation and in vivo tumour retention in acute myeloid leukaemia
European Journal of Nuclear Medicine and Molecular Imaging (2024)
-
Single-Cell Sequencing Reveals the Expression of Immune-Related Genes in Macrophages of Diabetic Kidney Disease
Inflammation (2024)
-
Single-cell RNA sequencing reveals the local cell landscape in mouse epididymal initial segment during aging
Immunity & Ageing (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
